Baker BROS. Advisors LP Buys Shares of 45,031 BioNTech SE (NASDAQ:BNTX)

Baker BROS. Advisors LP bought a new stake in BioNTech SE (NASDAQ:BNTX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 45,031 shares of the company's stock, valued at approximately $5,131,000.

Several other large investors have also modified their holdings of BNTX. Baird Financial Group Inc. raised its stake in shares of BioNTech by 14.2% during the 4th quarter. Baird Financial Group Inc. now owns 18,589 shares of the company's stock worth $2,118,000 after buying an additional 2,307 shares during the last quarter. Bamco Inc. NY increased its stake in shares of BioNTech by 12.7% during the 4th quarter. Bamco Inc. NY now owns 20,936 shares of the company's stock worth $2,386,000 after purchasing an additional 2,362 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in shares of BioNTech during the 4th quarter worth approximately $69,999,000. Alyeska Investment Group L.P. purchased a new stake in BioNTech in the 4th quarter valued at approximately $298,000. Finally, The Manufacturers Life Insurance Company grew its holdings in BioNTech by 9.8% during the 4th quarter. The Manufacturers Life Insurance Company now owns 22,983 shares of the company's stock valued at $2,619,000 after buying an additional 2,054 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Price Performance

NASDAQ BNTX traded down $1.46 on Friday, reaching $93.32. The company's stock had a trading volume of 436,974 shares, compared to its average volume of 919,827. The firm's 50 day moving average is $99.13 and its two-hundred day moving average is $109.63. The stock has a market cap of $22.39 billion, a PE ratio of -44.44 and a beta of 1.35. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same period last year, the company posted $1.90 EPS. The company's revenue was down 19.5% compared to the same quarter last year. As a group, sell-side analysts predict that BioNTech SE will post -3.88 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on BNTX. BMO Capital Markets boosted their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. Morgan Stanley decreased their target price on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research report on Tuesday. Canaccord Genuity Group reiterated a "buy" rating and issued a $171.44 price target on shares of BioNTech in a report on Tuesday, March 11th. HC Wainwright decreased their price objective on BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Finally, Truist Financial began coverage on BioNTech in a research note on Friday, January 10th. They issued a "buy" rating and a $172.00 target price for the company. Three research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $142.73.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.